open access
Effect of 6 weeks treatment with nebivolol on blood pressure reduction and echocardiographic indices in patients with essential hypertension
open access
Abstract
Material and methods The study included 76 male patients with mild to moderate (ESH/ESC: grade 1 and 2) essential hypertension (mean age: 43.6 ± 8.2 years). In all subjects at baseline and after 6 weeks of nebivolol treatment (5 mg once daily) or atenolol (50 mg once daily) (39 and 37 pts respectively) ABPM, Echo, ECG Holter and exercise test were performed.
Results In the nebivolol group SBP and DBP reduction was noticed in 87% and 69% of patients with essential hypertension. Based on ABPM mean SBP and DBP during the whole day, daytime and nighttime decreased: 13 ± 8/8 ± 8 mm Hg, 14 ± 9/10 ± 7 mm Hg and 9 ± 8/6 ± 8 mm Hg respectively (p < 0.01 for all differences).
In the nebivolol group E wave was increased between two examinations from 0.75 ± 0.15 m/s to 0.81 ± 0.2 m/s (p = 0.05), there were no significant changes in A wave 0.66 ± 0.08 m/s vs. 0.64 ± 0.1 m/s (NS).
Ratio E/A was increased during the time of observation from 1.14 ± 0.25 to 1.3 ± 0.23 (p < 0.001).
During the exercise test in the nebivolol group maximal SBP and DBP decreased by 18 ± 26 mm Hg (p < 0.001) and 3 ± 14 mm Hg (NS) respectively after 6 weeks of treatment.
Conclusions Our results indicate high antihypertensive efficacy of nebivolol in patients with essential hypertension. We also observed an improvement of selected echocardiographic indices. Nebivolol was not impairing the exercise tolerance in patients with essential hypertension.
Abstract
Material and methods The study included 76 male patients with mild to moderate (ESH/ESC: grade 1 and 2) essential hypertension (mean age: 43.6 ± 8.2 years). In all subjects at baseline and after 6 weeks of nebivolol treatment (5 mg once daily) or atenolol (50 mg once daily) (39 and 37 pts respectively) ABPM, Echo, ECG Holter and exercise test were performed.
Results In the nebivolol group SBP and DBP reduction was noticed in 87% and 69% of patients with essential hypertension. Based on ABPM mean SBP and DBP during the whole day, daytime and nighttime decreased: 13 ± 8/8 ± 8 mm Hg, 14 ± 9/10 ± 7 mm Hg and 9 ± 8/6 ± 8 mm Hg respectively (p < 0.01 for all differences).
In the nebivolol group E wave was increased between two examinations from 0.75 ± 0.15 m/s to 0.81 ± 0.2 m/s (p = 0.05), there were no significant changes in A wave 0.66 ± 0.08 m/s vs. 0.64 ± 0.1 m/s (NS).
Ratio E/A was increased during the time of observation from 1.14 ± 0.25 to 1.3 ± 0.23 (p < 0.001).
During the exercise test in the nebivolol group maximal SBP and DBP decreased by 18 ± 26 mm Hg (p < 0.001) and 3 ± 14 mm Hg (NS) respectively after 6 weeks of treatment.
Conclusions Our results indicate high antihypertensive efficacy of nebivolol in patients with essential hypertension. We also observed an improvement of selected echocardiographic indices. Nebivolol was not impairing the exercise tolerance in patients with essential hypertension.
Keywords
antihypertensive therapy; nebivolol; echocardiographic indices
About this articleTitle
Effect of 6 weeks treatment with nebivolol on blood pressure reduction and echocardiographic indices in patients with essential hypertension
Journal
Issue
Pages
243-251
Published online
2005-08-05
Bibliographic record
Nadciśnienie tętnicze 2005;9(4):243-251.
Keywords
antihypertensive therapy
nebivolol
echocardiographic indices
Authors
Elżbieta Florczak
Magdalena Makowiecka-Cieśla
Anna Klisiewicz
Bogna Puciłowska
Rafał Baranowski
Iwona Korzeniowska-Kubacka
Katarzyna Paschalis-Purtak
Hanna Janaszek-Sitkowska
Aleksander Prejbisz
Ewelina Mikocka
Andrzej Januszewicz
Piotr Hoffman